These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. Jørgensen JT Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518 [TBL] [Abstract][Full Text] [Related]
4. Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review. Mankoff DA; Farwell MD; Clark AS; Pryma DA JAMA Oncol; 2017 May; 3(5):695-701. PubMed ID: 28033451 [TBL] [Abstract][Full Text] [Related]
5. [Promotion of Personalized Medicine by Appropriate Utilization of Tumor Markers and Companion Diagnostics]. Tohda S Rinsho Byori; 2017 Mar; 65(3):314-316. PubMed ID: 30802016 [TBL] [Abstract][Full Text] [Related]
6. Companion Diagnostics and Molecular Imaging. Puranik AD; Kulkarni HR; Baum RP Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701 [TBL] [Abstract][Full Text] [Related]
7. Companion diagnostics: the key to personalized medicine. Foreword. Jørgensen JT Expert Rev Mol Diagn; 2015 Feb; 15(2):153-6. PubMed ID: 25597758 [TBL] [Abstract][Full Text] [Related]
8. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908 [TBL] [Abstract][Full Text] [Related]
9. Companion diagnostics for the targeted therapy of gastric cancer. Yoo C; Park YS World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953 [TBL] [Abstract][Full Text] [Related]
10. [Companion diagnostics in the era of personalized medicine--chairmen's introductory remarks]. Fukutsuka K; Takubo T Rinsho Byori; 2014 Apr; 62(4):378-80. PubMed ID: 25022067 [TBL] [Abstract][Full Text] [Related]
11. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine. Li M; Yu T; Hu YF Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099 [TBL] [Abstract][Full Text] [Related]
12. How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy. Mankoff DA; Farwell MD; Clark AS; Pryma DA Cancer J; 2015; 21(3):218-24. PubMed ID: 26049702 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. Myers MB Pharmgenomics Pers Med; 2016; 9():7-16. PubMed ID: 26858530 [TBL] [Abstract][Full Text] [Related]
15. The folate receptor as a rational therapeutic target for personalized cancer treatment. Assaraf YG; Leamon CP; Reddy JA Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975 [TBL] [Abstract][Full Text] [Related]
16. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776 [TBL] [Abstract][Full Text] [Related]
17. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing. Campbell MR Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388 [TBL] [Abstract][Full Text] [Related]
18. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. Philip R; Carrington L; Chan M Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257 [TBL] [Abstract][Full Text] [Related]
19. Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. Gebhart G; Flamen P; De Vries EG; Jhaveri K; Wimana Z J Nucl Med; 2016 Feb; 57 Suppl 1():81S-8S. PubMed ID: 26834107 [TBL] [Abstract][Full Text] [Related]